Across TCGA pan-cancer cohorts, FAM185A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FAM185A data layer compared with 23 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FAM185A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FAM185A expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where FAM185A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.636	0.158	.001	64	view →
LSCC	DFS	Median	II,III,IV	1.000	0.837	.006	16	view →
CCRCC	OS	Median	II,III,IV	0.971	0.840	.035	13	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	4	view →
HNSC	OS	Median	All	1.000	0.955	.023	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: FAM185A tumor-vs-normal RNA expression · all FAM185A data types